Apantamide plus docetaxel with hormone therapy for advanced prostate cancer
Part of Cancer, Hormones & metabolism, Kidney & urinary clinical trials.
This early-phase trial tests whether adding apantamide to hormone therapy (and possibly adding docetaxel chemotherapy) works better and is safe for men with high-volume spread of prostate cancer. It’s designed for people who have recently started hormone therapy and haven’t shown clear disease worsening yet.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man age 18 or older with prostate adenocarcinoma confirmed by lab tests (biopsy or cytology).
- Your scan shows high tumor burden, such as 4+ bone metastases or spread to organs/viscera.
- Your cancer is sensitive to hormone (endocrine) therapy, including after a recurrence following new or local treatment.
- You started androgen deprivation therapy (ADT) no more than 3 months ago, and there’s been no clear progression on scans and no major PSA rise since testosterone reached castration levels.
- You can take the study plan: apantamide plus ADT, and docetaxel as part of the treatment plan.
- Your overall health is good enough for treatment (ECOG 0–1) and your blood, liver, kidney, and blood-clotting tests are within required ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of hormone therapy, chemotherapy (docetaxel), and a targeted drug (apalutamide) with a focused ultrasound procedure (HIFU) for men with prostate cancer that has spread to many bones or organs. It may help control the cancer more effectively.
This trial is for men with metastatic prostate cancer that has already spread beyond the pelvis. It tests whether adding a chemotherapy drug (docetaxel) to the usual hormone therapy plus apalutamide can help control the cancer better than hormone therapy alone.
This trial looks at combining hormone therapy with either chemotherapy (docetaxel), a targeted pill (like abiraterone or enzalutamide), or radiation to the prostate tumor for men whose prostate cancer has spread but is still sensitive to hormones. The goal is to see which approach works best for controlling the cancer.
This trial tests whether adding a chemotherapy drug (docetaxel) to your current treatment (apalutamide) can help control prostate cancer that has spread and hasn't responded as well as hoped to apalutamide alone.
This trial tests if adding docetaxel chemotherapy helps men whose PSA hasn't dropped enough after at least 6 months of standard hormone therapy (ADT) plus an ARPI pill (like abiraterone or enzalutamide) for metastatic prostate cancer that still responds to hormones.
This trial tests a combination of two drugs (darolutamide plus hormone therapy) along with a low dose of chemotherapy (docetaxel) for men whose prostate cancer has spread to other parts of the body. It aims to see if this combined approach is safe and effective.
Hear when a new Cohort Studies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.